CTNM

$8.8110.01%-0.98

Contineum Therapeutics Inc (CTNM)

Contineum Therapeutics Inc Stock (CTNM) Forecast

The Contineum Therapeutics Inc (CTNM) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $8.29, representing a -5.89% decrease from the current price of $8.81. The highest analyst price target is $9.91, and the lowest is $6.68.

Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.

12-Month CTNM Price Target

Average 7.89 (-10.43% Downside)

Is Contineum Therapeutics Inc (CTNM) A Buy Now?

Oscillators

Name	Value	Action
RSI(14)	39.29	Neutral
STOCH(9,6)	74.58	Neutral
STOCHRSI(14)	65.82	Neutral
MACD(12,26)	-0.71	Buy
ADX(14)	29.55	Sell
William %R	-42.00	Neutral
CCI(14)	15.35	Neutral

Buy: 1 · Sell: 1 · Neutral: 5Summary: Neutral

Moving Averages

Period	Simple	Exponential
MA10	9.12 Sell	9.22 Sell
MA20	8.86 Sell	9.59 Sell
MA50	12.10 Sell	11.24 Sell
MA100	13.40 Sell	12.38 Sell
MA200	13.51 Sell	12.43 Sell

Buy: 0 · Sell: 10 · Neutral: 0Summary: Sell

According to our latest analysis, CTNM could be considered a Strong Sell, with 17 technical analysis indicators signaling 1 Buy signals, 11 signaling Sell signals and 5 Neutral signals. This might not be a good time to consider opening new positions on CTNM, as trading bearish markets can be challenging and may result in losses.

RSI (Relative Strength Index): The RSI(14) value of 39.29 indicates that CTNM is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
STOCH (Stochastic Oscillator): The STOCH value of 74.58 indicates that CTNM is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 65.82 indicates that CTNM is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
ADX (Average Directional Index): The ADX value of 29.55 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
CCI (Commodity Channel Index): A CCI(14) value of 15.35 indicates that CTNM is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.

Long-term CTNM price forecast for 2026, 2030, 2035, 2040, 2045 and 2050

Based on our analysis about Contineum Therapeutics Inc financial reports and earnings history, Contineum Therapeutics Inc (CTNM) stock could reach $9.11 by 2030, $13.98 by 2040 and $44.51 by 2050. See the projected annual prices until 2050 of the Contineum Therapeutics Inc stock below:

Contineum Therapeutics Inc (CTNM) is expected to reach an average price of $5.75 in 2035, with a high prediction of $11.06 and a low estimate of $0.1336. This indicates an -34.69% change from the last recorded price of $8.81.
Contineum Therapeutics Inc (CTNM) stock is projected to chart a bullish course in 2040, with an average price target of $5.15, representing an -41.57% change from its current level. The forecast ranges from a conservative $6.31 to a sky-high $13.98.
Our analysts predict Contineum Therapeutics Inc (CTNM) to change +167.77% by 2045, soaring from $23.71 to an average price of $23.59, potentially reaching $34.31. While $23.71 is the low estimate, the potential upside is significant.
Contineum Therapeutics Inc (CTNM) stock is expected to climb by 2050, reaching an average of $44.39, a +403.89% change from its current level. However, a wide range of estimates exists, with high and low targets of $44.51 and $36.76, respectively, highlighting the market's uncertainty.

Contineum Therapeutics Inc Stock (CTNM) Year by Year Forecast

Contineum Therapeutics Inc Stock (CTNM) Price Forecast for 2026

The predicted value for Contineum Therapeutics Inc (CTNM) in 2026 is set at an average of $13.17. Estimates vary from a peak of $17.79 to a trough of $6.68, indicating an +49.52% surge from the present price of $8.81.

Month	Average	Low	High	Change from today's price
December, 2026	$9.20	$6.68	$9.91	+4.47%

Contineum Therapeutics Inc Stock (CTNM) Price Forecast for 2027

For 2027, Stockscan's Analyst expects the average price target for Contineum Therapeutics Inc (CTNM) is $8.18, with a high forecast of $15.56 and a low forecast of $0.01. This indicates an -7.12% decrease from the last price of $8.81.

Month	Average	Low	High	Change from today's price
January, 2027	$12.11	$8.06	$14.35	+37.46%
February, 2027	$13.75	$10.26	$15.56	+56.04%
March, 2027	$10.83	$9.62	$15.28	+22.96%
April, 2027	$12.94	$10.19	$14.28	+46.87%
May, 2027	$10.68	$9.42	$14.09	+21.28%
June, 2027	$10.59	$9.83	$11.35	+20.22%
July, 2027	$8.93	$6.33	$14.22	+1.33%
August, 2027	$8.76	$6.71	$9.44	-0.53%
September, 2027	$5.37	$5.27	$9.40	-39.05%
October, 2027	$1.86	$1.31	$5.51	-78.93%
November, 2027	$1.43	$0.2244	$2.36	-83.75%
December, 2027	$0.9418	$0.01	$1.58	-89.31%

Contineum Therapeutics Inc Stock (CTNM) Price Forecast for 2028

In 2028, Contineum Therapeutics Inc (CTNM) is projected to reach an average price of $5.12, with a high projection of $11.72 and a low estimate of $0.1266. This indicates an -41.84% fall from the last price of $8.81.

Month	Average	Low	High	Change from today's price
January, 2028	$1.96	$1.20	$1.32	-77.80%
February, 2028	$0.9597	$1.21	$1.74	-89.11%
March, 2028	$1.43	$1.51	$1.22	-83.73%
April, 2028	$0.6633	$0.1266	$1.21	-92.47%
May, 2028	$5.31	$0.1476	$5.74	-39.74%
June, 2028	$6.86	$5.09	$8.41	-22.19%
July, 2028	$6.08	$5.19	$7.88	-30.98%
August, 2028	$6.05	$5.14	$8.19	-31.30%
September, 2028	$6.92	$5.31	$8.64	-21.41%
October, 2028	$7.02	$3.86	$8.16	-20.32%
November, 2028	$9.80	$6.30	$11.37	+11.19%
December, 2028	$8.43	$8.37	$11.72	-4.28%

Contineum Therapeutics Inc Stock (CTNM) Price Forecast for 2029

The 2029 price forecast for Contineum Therapeutics Inc Stock (CTNM) is $7.99 on average, with a high prediction of $13.77 and a low estimate of $0.0812. This represents an -9.33% decrease from the previous price of $8.81.

Month	Average	Low	High	Change from today's price
January, 2029	$8.40	$7.25	$9.67	-4.67%
February, 2029	$8.80	$7.36	$9.50	-0.06%
March, 2029	$9.17	$8.09	$11.28	+4.10%
April, 2029	$12.17	$6.89	$12.69	+38.10%
May, 2029	$9.91	$9.21	$12.19	+12.52%
June, 2029	$13.12	$9.13	$13.28	+48.92%
July, 2029	$9.56	$8.89	$13.77	+8.46%
August, 2029	$9.48	$6.90	$10.04	+7.63%
September, 2029	$4.99	$2.87	$7.66	-43.38%
October, 2029	$0.863	$0.423	$2.79	-90.20%
November, 2029	$2.25	$0.0812	$3.35	-74.51%
December, 2029	$7.15	$1.73	$9.12	-18.87%

Contineum Therapeutics Inc Stock (CTNM) Price Forecast for 2030

Contineum Therapeutics Inc Stock (CTNM) is expected to reach an average price of $5.24 in 2030, with a high forecast of $9.11 and a low forecast of $0.3268. This signifies an -40.48% decrease from the last price of $8.81.

Month	Average	Low	High	Change from today's price
January, 2030	$7.33	$5.74	$9.11	-16.80%
February, 2030	$7.48	$3.30	$7.79	-15.06%
March, 2030	$7.42	$3.94	$8.01	-15.82%
April, 2030	$4.15	$3.29	$7.79	-52.92%
May, 2030	$6.32	$3.74	$6.78	-28.26%
June, 2030	$2.76	$0.3268	$8.20	-68.63%
July, 2030	$2.78	$0.7898	$3.28	-68.39%
August, 2030	$1.79	$0.531	$3.55	-79.65%
September, 2030	$4.62	$3.23	$3.94	-47.55%
October, 2030	$4.26	$4.27	$4.04	-51.67%
November, 2030	$6.68	$5.61	$6.24	-24.23%
December, 2030	$7.33	$6.95	$6.81	-16.81%

Similar to CTNM